Using Queuing (and Simulation) to Reduce the Duration of Phase 1 Cancer Trials
“Phase 1 cancer studies, which guide dose selection for subsequent studies, are almost 3 times more prevalent than phase 3 studies and have a median study duration considerably longer than 2 years, which constitutes a major component of drug development time.” It takes a long, long time for new cancer treatments to get through the […]